Skip to content

Medtronic MDT Free cash flow

Free cash flow at other companies

Abbott logo
AbbottABT
$916M-1.8%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$546M
TFX
TeleflexTFX
$27.87M+676%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
Artivion logo
ArtivionAORT
-$6.85M+66.7%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%

Valuation

See full
Market cap$103.07B-6.9%
Enterprise value$130.33B-5.7%
P/E21.5×-2.3×
P/S2.8×-0.5×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Calculated from Medtronic’s reported figures.

The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medtronic's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medtronic's free cash flow?
Medtronic (MDT) reported free cash flow of $2.09B in Q1 2026.
How has Medtronic's free cash flow changed year-over-year?
Medtronic's free cash flow increased by 0.8% year-over-year, from $2.07B to $2.09B.
What is the long-term trend for Medtronic's free cash flow?
Over 5 years (2021 to 2026), Medtronic's free cash flow has grown at a 2.1% compound annual growth rate (CAGR), from $4.89B to $5.43B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.